Market Overview

UPDATE: J.P. Morgan Initiates bluebird bio at Overweight on Unique & Necessary Medical Products

Share:
Related BLUE
Why Drug Pricing Could Bring Volatility To The Biotech Sector This Year
10 Biotech Stories You Might've Missed This Week
Winners Circle 2014 Top Hedge Fund Managers: Healthcare Funds, Nine Of Top Ten Spots (Seeking Alpha)

In a report published on Monday, J.P. Morgan analyst Cory Kasimov initiated coverage on bluebird bio (NASDAQ: BLUE) with an Overweight rating and a $44 price target.

In the report, J.P. Morgan stated, "Catchy titles aside, bluebird bio is anything but “Old School.” Quite the contrary. In our view, BLUE – with its gene therapy platform – is one of the more potentially transformative and disruptive companies we've come across in some time. Importantly, however, this appears to be more than just a “big idea.” bluebird has already established promising proof-of-concept for its two lead products and is going after orphan indications with a very high unmet medical need that could bolster the ultimate probability of success."

bluebird bio closed on Friday at $30.65.

Latest Ratings for BLUE

DateFirmActionFromTo
Dec 2014Roth CapitalMaintainsBuy
Dec 2014WedbushReiteratesOutperform
Sep 2014Roth CapitalInitiates Coverage onBuy

View More Analyst Ratings for BLUE
View the Latest Analyst Ratings

Posted-In: Cory Kasimov J.P.MorganAnalyst Color Initiation Analyst Ratings

 

Related Articles (BLUE)

Around the Web, We're Loving...

Get Benzinga's Newsletters